US Stock MarketDetailed Quotes
BCDA BioCardia
- 2.180
- +0.059+2.78%
Close Jan 17 16:00 ET
- 2.180
- 0.0000.00%
Post 16:08 ET
9.99MMarket Cap-0.54P/E (TTM)
2.190High2.110Low16.13KVolume2.160Open2.121Pre Close34.68KTurnover0.43%Turnover RatioLossP/E (Static)4.58MShares8.85052wk High3.63P/B8.10MFloat Cap1.62552wk Low--Dividend TTM3.72MShs Float129.000Historical High--Div YieldTTM3.77%Amplitude1.625Historical Low2.149Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
BioCardia Stock Forum
2 mins ago
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
BioCardia (Nasdaq: BCDA) announced a successful consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) regarding its lead therapeutic asset, BCDA-01, for treating ischemic heart failure. The PMDA has invited BioCardia for a follow-up consultation after reviewing final clinical data with two-year follow-up from the CardiAMP Heart Failure...
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia has completed its Phase III CardiAMP HF trial, a randomized, double-blind, placebo-controlled study evaluating the CardiAMP Cell Therapy System for heart failure treatment. The trial enrolled 125 patients across 18 US hospitals, with 115 patients randomized 3:2 between treatment and control groups. The therapy, which received FDA Breakth...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
BioCardia (Nasdaq: BCDA), a leader in cardiovascular and pulmonary disease therapeutics, has announced the pricing of an upsized $7.2 million public offering. The offering includes 2,400,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 2,400,000 shares at $3.00 per share and accompanying warrant. The warrants have a 5-year expirati...
No comment yet